(News Bulletin 247) – Deutsche Bank announced on Tuesday that it had downgraded its recommendation on Sanofi shares, going to ‘sell’ on the value, against ‘hold’ so far.
In a research note, Deutsche Bank analysts return to the first quarter publication deemed ‘mixed’ by the laboratory, while worrying about a possible arrival at a peak in sales of Dupixent.
While they consider the success of the recent clinical study in COPD a clear victory, professionals do not expect the next data on the compound to generate the same enthusiasm, now that its mechanism of action is proven. .
The research department adds that the filing of a new registration application should remain dependent on the publication of new data in the first half of 2024, when the clinical results on Nucala, another anti-COPD treatment, should also be published. developed by GSK.
Its target price remains unchanged, at 90 euros.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
